# JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Source: https://onco.cc/trials/nct06391944/  
OnCo record `nct06391944` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by Shanghai JMT-Bio Inc., active and no longer recruiting.

## Summary

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations is a phase 2 interventional study registered as NCT06391944 by Shanghai JMT-Bio Inc., with 161 participants enrolled, started 2021-11-21 and due to reach its primary completion in 2023-05-17. Interventions recorded: JMT101 Injection and Osimertinib tablet.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06391944
- Phase: 2
- Setting: A Phase 2, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-Small Cell Lung Cancer With EGFR Common Mutations
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 161

## Sources

- ClinicalTrials.gov NCT06391944: https://clinicaltrials.gov/study/NCT06391944

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06391944.json